Pharmaceutical company Eli Lilly ... it's a once-a-day weight management pill. However, the pharmaceutical firm ran into some trouble two years into developing and testing the drug, finding ...

Eli Lilly reported ... market the drug for weight loss later this year, and early next year for diabetes. The F.DA. could take months and possibly longer to review the company’s trial data ...

Eli Lilly’s new GLP-1 weight loss drug, in pill form, would be more affordable than Ozempic Orforglipron, which could become the first GLP-1 pill — a much more convenient option — is a step ...

Shares of Eli Lilly (LLY) jumped 16% Thursday morning to lead S&P 500 gainers after the pharmaceutical company released clinical trial results for its oral weight-loss drug that "demonstrated ...

Eli Lilly's oral GLP-1 medicine aced a phase 3 study. It should become a new growth driver for the company. There are other reasons to invest in the pharmaceutical leader. Zepbound's prospects ...

Eli Lilly's stock boomed April 17 after announcing a new experimental pill that caused nearly 8% weight loss at certain dosages ... approval by the Food and Drug Administration (FDA).

April 17 (UPI) --People diagnosed with type 2 diabetes might benefit soon from Eli Lilly's new orforglipron weight loss drug following its latest clinical testing, the Indianapolis-based drugmaker ...

Eli Lilly (NYSE: LLY) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a weight loss medicine that's already generating more than $1 billion in ...